Free Access
Med Sci (Paris)
Volume 20, Number 10, Octobre 2004
Page(s) 882 - 886
Section M/S revues
Published online 15 October 2004
  1. Carpenter CC, Cooper DA, Fischl MA, et al. Antiretroviral therapy for HIV infection in adults. JAMA 2000; 283 : 381–90. [Google Scholar]
  2. Gayle HD, Hill GL. Global impact of human immunodeficiency virus and AIDS. Clin Microbiol Rev 2001; 14 : 327–35. [Google Scholar]
  3. Cock KM, Weiss HA. The global epidemiology of HIV/AIDS. Trop Med Int Health 2000; 5 : A3–9. [Google Scholar]
  4. Cohen J. Confronting the limits of success. Science 2002; 296 : 2320–4. [Google Scholar]
  5. Yeni PG, Hammer SM, Carpenter CCJ, et al. Antiretroviral treatment for adult HIV infection in 2002 : updated recommendations of the International AIDS Society-USA panel. JAMA 2002; 288 : 222–35. [Google Scholar]
  6. Furman PA, Fyfe JA, St Clair MH, et al. Phosphorylation of 3’-azido-3’-deoxythymidine and selective interactions of the 5’-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA 1986; 83 : 8333–7. [Google Scholar]
  7. Hart GJ, Orr DC, Penn CR, et al. Effects of 2’-deoxy-3’-thiacytidine (3TC) 5’-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta and gamma. Antimicrob Agents Chemother 1992; 37 : 918–20. [Google Scholar]
  8. Spence RA, Kati WM, Anderson KS, et al. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Science 1995; 267 : 988–92. [Google Scholar]
  9. Gu Z, Quan Y, Li Z, et al. Effects of non-nucleosides inhibitors of human immunodeficiency virus type 1 in cell-free recombinant reverse transcriptase assay. J Biol Chem 1995; 270 : 31046–51. [Google Scholar]
  10. Boden D, Markowitz M. Resistance to human immunodeficiency type 1 protease inhibitors. Antimicrob Agents Chemother 1998; 42 : 2775–83. [Google Scholar]
  11. Quiros-Roldan E, Signorini S, Castelli F, et al. Analysis of HIV-1 mutation patterns in patients failing antiretroviral therapy. J Clin Lab Anal 2001; 15 : 43–6. [Google Scholar]
  12. Lorenzi P, Opravil M, Hirschel B, et al. Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV cohort study. AIDS 1999; 13 : F17–21. [Google Scholar]
  13. Johnson VA, Brun-Vésinet F, Clotet B, et al. Drug resistance mutations in HIV-1. Top HIV Med 2003; 11 : 215–21. [Google Scholar]
  14. Wainberg MA, Brenner BG. HIV-1 drug resistance. In : Essex M, et al., eds. AIDS in Africa, 2nd ed. Dordrech : Kluwer Press 2002 : 345–54. [Google Scholar]
  15. Brenner BG, Wainberg MA. The role of antiretrovirals and drug resistance in vertical transmission. Ann NY Acad Sci 2000; 918 : 9–15. [Google Scholar]
  16. Gunthard HF, Wong JK, Ignacio CC, et al. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J Virol 1998; 72 : 2422–8. [Google Scholar]
  17. Kuritzkes D. Progress in drug-resistance testing in the management of antiretroviral therapy. PRN Notebook 1999; 4 : 14–8. [Google Scholar]
  18. Larder BA, Kemp SD, Hertogs K, et al. Quantitative prediction of HIV-1 phenotypic drug resistance from genotypes : the virtual phenotype (virtual phenotype). Antiviral Ther 2000; 5 : 49 (abstract). [Google Scholar]
  19. Sheldon JG, Condra JH. Genotypic analysis methods for detection of drug resistance mutations in the HIV-1 proteinase and reverse transcriptase genes. Antiviral Ther 1999; 4 : 135–42. [Google Scholar]
  20. ONUSIDA/OMS 2003. Le point sur l’épidémie de sida.1-39. [Google Scholar]
  21. World Health Organization. Safe and effective use of antiretroviral treatments in adults. With particular references to resource limited setting. Geneva : WHO, 2000 : 1-21. [Google Scholar]
  22. Descamps D, Collin G, Letourneur F, et al. Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents : in vitro phenotypic and genotypic analysis. J Virol 1997; 71 : 8893–8. [Google Scholar]
  23. Loemba H, Brenner B, Parniak MA, et al. Genotypic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against non-nucleoside inhibitors of RT. Antimicrob Agents Chemother 2002; 46 : 2087–94. [Google Scholar]
  24. Caride E, Hertogs K, Larder B, et al. Genotypic and phenotypic evidence of different drug-resistance mutation patterns between B and non-B subtype isolates of human immunodeficiency virus type 1 found in Brazilian patients failing HAART. Virus Gene 2001; 23 : 193–202. [Google Scholar]
  25. Loemba H, Brenner B, Parniak MA, et al. Polymorphisms of cytotoxic T-lymphocyte (CTL) and T-helper epitopes within reverse transcriptase (RT) of HIV-1 subtype C from Ethiopia and Botswana following selection of antiretroviral drug resistance. Antiviral Res 2002; 56 : 129–42. [Google Scholar]
  26. Brenner B, Turner D, Oliveira M, et al. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 2003; 17 : 1–5. [Google Scholar]
  27. Eshleman SH, Guay LA, Mwatha A, et al. Characterization of nevirapine resistance mutations in women with subtype A Vs. D HIV-1 6-8 weeks after single-dose nevirapine (HIVNET 012). J Acquir Immune Def Syndr 2004; 35 : 126–30. [Google Scholar]
  28. Alves AS, Basso CR, Souza RA, et al. Virological efficacy of the people with HIV/AIDS in ARV therapy in accordance with the time of treatment in centre of reference and training in DST/AIDS, Sao Paulo, Brazil. Paris, France : 2nd IAS conference on HIV pathogenesis and treatment, 2003 : 685 (abstract). [Google Scholar]
  29. Weidle PJ, Downing R, Sozi C, et al. Development of phenotypic and genotypic resistance to antiretroviral therapy in the UNAIDS HIV drug access initiative-Uganda. AIDS 2003; 17 : S39–48. [Google Scholar]
  30. Djomand G, Roels T, Ellerbrock T, et al. Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Côte d’Ivoire. AIDS 2003; 17 : S5–15. [Google Scholar]
  31. Laniece I, Ciss M, Desclaux A, et al. Adherence to HAART and its principal determinants in a cohort of Senegalese adults. AIDS 2003; 17 : S103–8. [Google Scholar]
  32. Hogg RS, Yip B, Chan K, et al. Nonadherence to triple combination therapy is predictive of AIDS progression and death in HIV-positive men and women. San Fransisco, USA : 7th Conference on retroviruses and opportunistic infections, 2000 : 73 (abstract). [Google Scholar]
  33. Amoroso A, Davis CE, Redfield RR. Antiretroviral therapy in resource-limited settings. In : Essex M, et al., eds. AIDS in Africa, 2nd ed. Dordrech : Kluwer Press, 2002 : 322–33. [Google Scholar]
  34. Liechty CA, Bansberg DR. Doubts about DOT : antiretroviral therapy for resource-poor countries. AIDS 2003; 17 : 1383–7. [Google Scholar]
  35. Farmer P, Leandre F, Mukherjee JS, et al. Community-based approaches to HIV treatment in resource-poor settings. Lancet 2001; 358 : 404–9. [Google Scholar]
  36. Hirsch MS, Brun-Vézinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1. Recommendations of an international AIDS society-USA panel. Clin Infect Dis 2003; 37 : 113–28. [Google Scholar]
  37. Durant J, Clevenbergh P, Halfon P, et al. Drug-resistance genotyping in HIV-1 therapy : the VIRADAPT randomized controlled trial. Lancet 1999; 353 : 2195–9. [Google Scholar]
  38. Baxter JD, Mayers D, Wentworth DN, et al. Final results of CPCRA 046 : a pilot study of antiretroviral management based on plasma genotypic antiretroviral resistance testing (GART) in patients failing antiretroviral therapy. Antiviral Ther 1999; 4 : 61 (abstract). [Google Scholar]
  39. Ravela J, Betts BJ, Brun-Vezinet F, et al. HIV-1 protease and reverse transcriptase patterns responsible of discordances between genotypic drug resistance interpretation algorithms. J AIDS 2003; 33 : 8–14. [Google Scholar]
  40. Götte M, Wainberg MA. Biochemical mechanisms involved in overcoming HIV resistance to nucleoside inhibitors of reverse transcriptase. Drug Resist Updates 2000; 3 : 30–8. [Google Scholar]
  41. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda : HIVNET 012 randomised trial. Lancet 1999; 354 : 795–802. [Google Scholar]
  42. Van Leth F, Hassink E, Phanuphak P, et al. The 2NN study : a randomised comparative open label trial of first-line antiretroviral therapy with regimens containing either nevirapine, efavirenz, or both drugs combined in addition to stavudine and lamivudine. Boston, USA : 10th Conference on retroviruses and opportunistic infections, 2003 : 176 (abstract). [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.